These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38749111)

  • 1. PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.
    Naffrichoux J; Poupin P; Pouillot W; Linassier C; Rioux-Leclercq N; De Vries-Brilland M; Mourey L; Laguerre B; Oudard S; Gross-Goupil M; Mousset C; Gravis G; Rolland F; Moise L; Emambux S; Vassal C; Zanetta S; Penel N; Albiges L; Fromont G; Cancel M
    Eur J Cancer; 2024 Jul; 205():114121. PubMed ID: 38749111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma.
    Mondorf Y; Mikuteit M; Ivanyi P; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief CG; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Steffens S; Erlmeier F
    Urol Int; 2022; 106(11):1168-1176. PubMed ID: 35654002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of PD-L1, PD-L2, and Immune Response Markers in Matched Renal Clear Cell Carcinoma Primary and Metastatic Tissue Specimens.
    Basu A; Yearley JH; Annamalai L; Pryzbycin C; Rini B
    Am J Clin Pathol; 2019 Jan; 151(2):217-225. PubMed ID: 30346474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
    Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
    Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
    de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
    Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
    Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
    Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.
    Flaifel A; Xie W; Braun DA; Ficial M; Bakouny Z; Nassar AH; Jennings RB; Escudier B; George DJ; Motzer RJ; Morris MJ; Powles T; Wang E; Huang Y; Freeman GJ; Choueiri TK; Signoretti S
    Clin Cancer Res; 2019 Oct; 25(20):6080-6088. PubMed ID: 31371341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study.
    Erlmeier F; Steffens S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Ivanyi P;
    Clin Genitourin Cancer; 2021 Feb; 19(1):53-59.e1. PubMed ID: 32778505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma.
    Zhang X; Yin X; Zhang H; Sun G; Yang Y; Chen J; Zhu X; Zhao P; Zhao J; Liu J; Chen N; Wang J; Shen P; Zeng H
    BMC Cancer; 2019 Apr; 19(1):360. PubMed ID: 30992011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas.
    Yeong J; Zhao Z; Lim JCT; Li H; Thike AA; Koh VCY; Teh BT; Kanesvaran R; Toh CK; Tan PH; Khor LY
    J Clin Pathol; 2020 Aug; 73(8):463-469. PubMed ID: 31980560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
    Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
    Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer.
    Möller K; Fraune C; Blessin NC; Lennartz M; Kluth M; Hube-Magg C; Lindhorst L; Dahlem R; Fisch M; Eichenauer T; Riechardt S; Simon R; Sauter G; Büscheck F; Höppner W; Matthies C; Doh O; Krech T; Marx AH; Zecha H; Rink M; Steurer S; Clauditz TS
    Int Urol Nephrol; 2021 Dec; 53(12):2493-2503. PubMed ID: 33797012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma.
    Tsimafeyeu I; Khasanova A; Stepanova E; Gordiev M; Khochenkov D; Naumova A; Varlamov I; Snegovoy A; Demidov L
    Clin Transl Oncol; 2017 Feb; 19(2):265-268. PubMed ID: 27379982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
    Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
    Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.
    McKay RR; Bossé D; Xie W; Wankowicz SAM; Flaifel A; Brandao R; Lalani AA; Martini DJ; Wei XX; Braun DA; Van Allen E; Castellano D; De Velasco G; Wells JC; Heng DY; Fay AP; Schutz FA; Hsu J; Pal SK; Lee JL; Hsieh JJ; Harshman LC; Signoretti S; Motzer RJ; Feldman D; Choueiri TK
    Cancer Immunol Res; 2018 Jul; 6(7):758-765. PubMed ID: 29748390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry.
    Kim SH; Park WS; Park EY; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
    PLoS One; 2017; 12(6):e0179610. PubMed ID: 28654655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma.
    Sekino Y; Han X; Kobayashi G; Babasaki T; Miyamoto S; Kobatake K; Kitano H; Ikeda K; Goto K; Inoue S; Hayashi T; Teishima J; Sakamoto N; Sentani K; Oue N; Yasui W; Matsubara A
    Oncology; 2021; 99(4):240-250. PubMed ID: 33588420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression in papillary renal cell carcinoma.
    Motoshima T; Komohara Y; Ma C; Dewi AK; Noguchi H; Yamada S; Nakayama T; Kitada S; Kawano Y; Takahashi W; Sugimoto M; Takeya M; Fujimoto N; Oda Y; Eto M
    BMC Urol; 2017 Jan; 17(1):8. PubMed ID: 28086852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Non-Clear Cell Renal Cell Carcinoma.
    Chrabańska M; Szweda-Gandor N; Rynkiewicz M; Hraboš D; Drozdzowska B
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.